BACKGROUND: Development of treatments for progressive multiple sclerosis (MS) is challenged by the lack of sensitive and treatment-responsive biomarkers of intrathecal inflammation. OBJECTIVE: To validate the responsiveness of cerebrospinal fluid (CSF) inflammatory biomarkers to treatment with natalizumab and methylprednisolone in progressive MS and to examine the relationship between CSF inflammatory and tissue damage biomarkers. METHODS: CSF samples from two open-label phase II trials of natalizumab and methylprednisolone in primary and secondary progressive MS. CSF concentrations of 20 inflammatory biomarkers and CSF biomarkers of axonal damage (neurofilament light chain (NFL)) and demyelination were analysed using electrochemiluminescent assay and enzyme-linked immunosorbent assay (ELISA). RESULTS: In all, 17 natalizumab- and 23 methylprednisolone-treated patients had paired CSF samples. CSF sCD27 displayed superior standardised response means and highly significant decreases during both natalizumab and methylprednisolone treatment; however, post-treatment levels remained above healthy donor reference levels. Correlation analyses of CSF inflammatory biomarkers and NFL before, during and after treatment demonstrated that CSF sCD27 consistently correlates with NFL. CONCLUSION: These findings validate CSF sCD27 as a responsive and sensitive biomarker of intrathecal inflammation in progressive MS, capturing residual inflammation after treatment. Importantly, CSF sCD27 correlates with NFL, consistent with residual inflammation after anti-inflammatory treatment being associated with axonal damage.
BACKGROUND: Development of treatments for progressive multiple sclerosis (MS) is challenged by the lack of sensitive and treatment-responsive biomarkers of intrathecal inflammation. OBJECTIVE: To validate the responsiveness of cerebrospinal fluid (CSF) inflammatory biomarkers to treatment with natalizumab and methylprednisolone in progressive MS and to examine the relationship between CSF inflammatory and tissue damage biomarkers. METHODS: CSF samples from two open-label phase II trials of natalizumab and methylprednisolone in primary and secondary progressive MS. CSF concentrations of 20 inflammatory biomarkers and CSF biomarkers of axonal damage (neurofilament light chain (NFL)) and demyelination were analysed using electrochemiluminescent assay and enzyme-linked immunosorbent assay (ELISA). RESULTS: In all, 17 natalizumab- and 23 methylprednisolone-treated patients had paired CSF samples. CSF sCD27 displayed superior standardised response means and highly significant decreases during both natalizumab and methylprednisolone treatment; however, post-treatment levels remained above healthy donor reference levels. Correlation analyses of CSF inflammatory biomarkers and NFL before, during and after treatment demonstrated that CSF sCD27 consistently correlates with NFL. CONCLUSION: These findings validate CSF sCD27 as a responsive and sensitive biomarker of intrathecal inflammation in progressive MS, capturing residual inflammation after treatment. Importantly, CSF sCD27 correlates with NFL, consistent with residual inflammation after anti-inflammatory treatment being associated with axonal damage.
Authors: Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky Journal: N Engl J Med Date: 2016-12-21 Impact factor: 91.245
Authors: M Ravnborg; M Blinkenberg; F Sellebjerg; M Ballegaard; S Helweg Larsen; P Soelberg Sørensen Journal: Mult Scler Date: 2005-02 Impact factor: 6.312
Authors: K Blennow; P Fredman; A Wallin; C G Gottfries; I Karlsson; G Långström; I Skoog; L Svennerholm; C Wikkelsö Journal: Eur Neurol Date: 1993 Impact factor: 1.710
Authors: Wangko Lundström; Christina Hermanrud; Maria Sjöstrand; Susanna Brauner; Marie Wahren-Herlenius; Tomas Olsson; Virginija Karrenbauer; Jan Hillert; Anna Fogdell-Hahn Journal: Mult Scler Date: 2014-05-12 Impact factor: 6.312
Authors: Muktha S Natrajan; Mika Komori; Peter Kosa; Kory R Johnson; Tianxia Wu; Robin J M Franklin; Bibiana Bielekova Journal: Ann Clin Transl Neurol Date: 2015-10-27 Impact factor: 4.511
Authors: Raju Kapoor; Kathryn E Smith; Mark Allegretta; Douglas L Arnold; William Carroll; Manuel Comabella; Roberto Furlan; Christopher Harp; Jens Kuhle; David Leppert; Tatiana Plavina; Finn Sellebjerg; Caroline Sincock; Charlotte E Teunissen; Ilir Topalli; Florian von Raison; Elizabeth Walker; Robert J Fox Journal: Neurology Date: 2020-07-16 Impact factor: 9.910
Authors: Robert J Fox; Paola Raska; Christian Barro; Matthew Karafa; Victoria Konig; Robert A Bermel; Marianne Chase; Christopher S Coffey; Andrew D Goodman; Eric C Klawiter; Robert T Naismith; Jens Kuhle Journal: Mult Scler Date: 2021-02-26 Impact factor: 6.312
Authors: Zara A Ioannides; Peter A Csurhes; Andrew Swayne; Philippe Foubert; Blake T Aftab; Michael P Pender Journal: Mult Scler J Exp Transl Clin Date: 2021-06-03
Authors: Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei Journal: Int J Mol Sci Date: 2022-03-21 Impact factor: 5.923